浙江医药(600216.SH)筹划分拆控股子公司新码生物于香港联交所上市

Core Viewpoint - Zhejiang Medicine (600216.SH) plans to spin off its subsidiary Zhejiang Xima Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange to enhance the development of its biopharmaceutical segment and improve overall profitability and core competitiveness [1] Group 1 - The spin-off aims to better utilize capital market resources and broaden financing channels [1] - The proposed listing will not result in the loss of control over Xima Biopharmaceutical by Zhejiang Medicine [1] - The spin-off is not expected to adversely affect the operations of other business segments or the overall profitability of the company [1]